CAS 913611-97-9 High Quality Bulk Brexpiprazole with Best Price

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: ST-Brexpiprazole
• Certification: ISO 9001, FDA
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Use: Healthy
• MOQ: 10g
• Molecular Formula: Brexpiprazole
• CAS: 913611-97-9
• Einecs: /
• Appearance: Powder
• Colour: White
• Sample: Available
• Delivery: 3-5day
• Spe: Free Sample
• Capacity: 50000kg/Mouth
• Supply Type: OEM/ODM
• Quality: Industrial
• Type: Pharmaceutical Intermediates
• Certificate: ISO 9001
• Transport Package: 1kg/Bag, 25kg/Drum
• Specification: 99%
• Trademark: SENTIAN
• Origin: China
• Production Capacity: 50000 Kg Per Month

Product Description

Description

Brexpiprazole is an atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression.  Although Brexpiprazole failed Phase II clinical trials for ADHD, Brexpiprazole has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).

 

 

 

COA

Item	Specification	Test result
Appearance	white powder	Conforms
Assay	99%	Conforms
Heavy metal	≤10ppm	Conforms
Lead	≤2.0ppm	Conforms
As	≤2.0ppm	Conforms
Ca	≤1.0ppm	Conforms
Me	≤0.1ppm	Conforms
Total aerobic microbial count	≤1000CFU/g	Conforms
Total moulds&yeast count	≤100CFU/g	Conforms
Enterobacterial	≤10MPN/g	Conforms
Salmonella	N.D/25g	Conforms
Escherichia coli	N.D/10g	Conforms
Staphylococcus aureus	N.D/10g	Conforms
Pseudomonas aeruginosa	N.D/10g	Conforms
Conclusion: Conform with specification.

 

 

Brexpiprazole Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. High doses or long  term use of brexpiprazole can cause a serious movement disorder that may not be reversible. Symptoms of this disorder include uncontrollable muscle movements of your lips, tongue, eyes, face, arms, or legs.  The longer you take brexpiprazole, the more likely you are to develop a serious movement disorder. The risk of this side effect is higher in women and older adults.

The most common adverse events associated with brexpiprazole all doses of brexpiprazole cumulatively greater than or equal to 5% vs. placebo were upper respiratory tract infection (6.9% vs. 4.8%), akathisia (6.6% vs. 3.2%), weight gain (6.3% vs. 0.8%) and nasopharyngitis (5.0% vs. 1.6%). Drug interactions Based on information given on the consent forms, Brexpiprazole seems brexpiprazole is a substrate of CYP2D6 and CYP3A4, like its predecessor aripiprazole. Participants in the clinical trials are advised to avoid grapefruit, Seville oranges and related citruses.

Company